Keros Therapeutics (KROS) Net Margin (2019 - 2025)
Keros Therapeutics (KROS) has disclosed Net Margin for 6 consecutive years, with 6173.95% as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Net Margin fell 1523418.0% year-over-year to 6173.95%, compared with a TTM value of 35.68% through Dec 2025, down 22569082.0%, and an annual FY2025 reading of 35.68%, changed N/A over the prior year.
- Net Margin was 6173.95% for Q4 2025 at Keros Therapeutics, down from 51.74% in the prior quarter.
- Across five years, Net Margin topped out at 1588500.0% in Q1 2021 and bottomed at 493000.0% in Q3 2023.
- Average Net Margin over 5 years is 65606.11%, with a median of 151.66% recorded in 2022.
- The sharpest move saw Net Margin crashed -158863437bps in 2022, then skyrocketed 47935155bps in 2024.
- Year by year, Net Margin stood at 38.77% in 2021, then soared by 491bps to 151.48% in 2022, then crashed by -18678bps to 28141.96% in 2023, then soared by 132bps to 9060.24% in 2024, then tumbled by -168bps to 6173.95% in 2025.
- Business Quant data shows Net Margin for KROS at 6173.95% in Q4 2025, 51.74% in Q3 2025, and 168.96% in Q2 2025.